Loading company
NeuroPace Inc
NPCE · Nasdaq · ·
Next earnings: November 3, 2026
$13.97-1.3%Sep 29 close
- 1M
- -3.1%
- 6M
- +8.8%
- 1Y
- +35.5%
- 5Y
- -13.6%
NPCE · Nasdaq · ·
Next earnings: November 3, 2026
$13.97-1.3%Sep 29 close
NeuroPace Inc is scheduled to report next on November 3, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $22.8M | $19.5M | +17.05% |
| Profit | -$6.2M | -$8.7M | +28.33% |
| Profit per share | -$0.18 | -$0.26 | +30.77% |
| Free Cash Flow | -$4M | -$2.3M | -78.70% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“Second-quarter performance showed continued momentum in our core RNS business driven by increased adoption within our current focal epilepsy indication,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Inc. Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from NeuroPace Inc’s Item 2.02 8-K filed August 11, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
NeuroPace Inc has no earnings call transcript available.